
Summary of results for patients diagnosed in England 2023





of patients were diagnosed at stage 1/2
32% in 2022, 30% in 2021 & 29% in 2020

of patients presented with stage 4 lung cancer 47% in 2022, 49% in 2021 & 50% in 2020

of patients were diagnosed after emergency admission 33% in 2022, 29% in 2021 & 29% in 2020





83 days

Median time from referral to **surgery** in NSCLC stage 1/2 Median time from referral to **SACT** in NSCLC stage 3B-4

66 days



Treatment allocation

2020

2021

Treatment with curative intent for Non-Small Cell Lung Cancer (NSCLC)



of patients with NSCLC (stage 1/2, Performance Status (PS) 0-2) received treatment with curative intents.

2022

2023





80% in 2022 **80%** in 2021 **81%** in 2020



of patients with NSCLC (stage 3A, PS 0-2) received treatment with curative intent**



N/A

61% in 2022 **61%** in 2021

60% in 2020

Surgery for Non-Small Cell Lung Cancer (NSCLC)



of patients with NSCLC had surgical treatment for their cancer





18% in 2022 17% in 2021 16% in 2020

Systemic Anti-Cancer Therapy (SACT) for Non-Small Cell Lung Cancer (NSCLC)



of patients with NSCLC (stage 3B - 4, PS 0-1) received SACT





62% in 2022 **63%** in 2021 **60%** in 2020

Systemic Anti-Cancer Therapy (SACT) for Small Cell Lung Cancer (SCLC)



of patients with SCLC received treatment with SACT



≥70%

Audit standard

73% in 2022 **72%** in 2021 **69%** in 2020

Survival outcomes

18,653 patients were diagnosed between 1 January and 30 June 2023. For these patients:

Median survival

One year survival

358 days

281 days in 2022 **267** days in 2021

242 days in 2020



46% in 2022 44% in 2021

43% in 2020

Data quality

Completeness of key routine data items

Stage

Performance status

Basis of diagnosis

Morphology

Lung Clinical Nurse Specialist at diagnosis

Audit standard

Smoking status





















